Vittamed in the News

Innovators in pediatric care compete for grants

WASHINGTONMarch 2, 2016 /Washington Post/ -- Since 2013, the consortium’s 51 grant-winners have raised an additional $19 million in capital. Previous years’ winners include Velano Vascular, which earlier this year received regulatory clearance for its needle-free blood-draw device, and Vittamed, which recently snagged $10 million in venture capital for a device that uses ultrasound technology to monitor children with traumatic brain injuries. (The current procedure requires drilling a hole in the skull and inserting a catheter into the brain.)

Full Text: Washington Post

Vittamed secures $10M in venture funding for commercialization of non-invasive Intracranial Pressure (ICP) system

BOSTONOct. 16, 2015 /PRNewswire/ -- Vittamed Corporation, a neurodiagnostic company that has developed a novel non-invasive intracranial pressure monitor announced that it has secured $10M in Series A financing by Xeraya Capital Labuan Ltd ("Xeraya Capital") via a special purpose vehicle led the investment round (committed $8M) with additional commitment from an existing investor Imprimatur Capital and other investors. The funding will support product launch in EuropeAustralia, and other countries, a 510k submission to the FDA, and commercialization in the US.

Full Text: PRNewswire

8 News Now:  Interstellar brain monitoring

<...> “This could potentially not only benefit astronauts, but also millions of people on earth,” explained Dr. Bershad.

Using an ultrasound, the device measures blood flow through the eye artery. <...>

NEW TECHNOLOGY: In collaboration with the Kaunas Institute of Technology in Lithuania, Eric Bershad, M.D., of Baylor College of Medicine and the National Space Biomedical Research Institute have developed a new non-invasive way to measure ICP and assess elevated brain pressure in patients and perhaps future astronauts. Dr. Bershad told Ivanhoe that the Vittamed device uses ultrasound-based measurements through the eye artery, “since the ophthalmic artery runs both inside and outside of the skull, the intracranial pressure will affect the way blood flows in the part of the artery inside the brain. This can be compared with the flow in the extracranial eye artery segment. The differences can then be analyzed to determine the intracranial pressure.” Another device developed to measure brain volume changes is Cerebrotech which can detect early stages of brain bleeding or swelling using low energy radio waves. The future vision of the device is to allow astronauts to continuously wear it to monitor changes in cerebral fluids.

Full text and Source with Video:  8 News Now

Press Release: Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors

August 29, 2014

Vittamed Corporation, a neurodiagnostics medical device company announced today that T. (Teo) Forcht Dagi, MD, DmedSc, MPH, MBA, FACS, FRCSEd  was appointed to the company’s Board of Directors.

Press Release: Vittamed Received CE Mark Approval for Non-invasive Intracranial Pressure Meter and Non-invasive Cerebrovascular Autoregulation Monitor

"CE approval for both devices is not only an important milestone for our company as we move toward commercialization but also an important advance in patient care," stated  Dr. Remis Bistras, the CEO of Vittamed.  "Invasive options for intracranial pressure measurement and for cerebral perfusion monitoring have historically been limited by risk, inconvenience, and high costs. Our monitors, in contrast, add no material risk. They are totally non-invasive and may be deployed routinely whenever and wherever indicated, including the outpatient setting. "

Full text: PRNewswire

Bio-News Texas about Vittamed: NBCM Scientists Research New Non-invasive Intracranial Pressure Measurement Device In Patients And Potentially Astronauts 

Two Baylor College of Medicine scientists are leaders of a clinical research study of a non-invasive intracranial pressure measurement device launched by the National Space Biomedical Research Institute (NSBRI) and the device’s developer UAB Vittamed. The study will include the monitoring of neurological patients, as a prelude to possible future use with astronauts.

Source: Bio News Texas

Medical Device Daily: NSBRI evaluates use of Vittamed's intracranial pressure monitor

By Omar Ford

A problem that some astronauts face is the development of serious visual impairment conditions that are associated symptoms suggestive of elevated pressure on the brain, or increased intracranial pressure. This has prompted the National Space Biomedical Research Institute (NSBRI), a non-profit organization that is funded by NASA to partner with Vittamed, a med-tech firm that has developed a device to could non-invasively measure absolute intracranial pressure (ICP), to initiate a clinical research study.

The independent study, which will evaluate the Vittamed 205 device, will include the monitoring of neurological patients, as a prelude to possible future use with astronauts. ...Full text

Source: Medical Device Daily

Press Release: New non-invasive intracranial pressure measurement device used to assess elevated brain pressure in patients may also benefit astronauts. Boston - Dec. 18, 2013

A clinical research study of a non-invasive intracranial pressure measurement device has been launched by the National Space Biomedical Research Institute (NSBRI) and Vittamed, the developer of the device. The study will include the monitoring of neurological patients, as a prelude to possible future use with astronauts.

Full text: Reuters

Euronews about non-invasive intracranial pressure monitoring (the European Commission Brainsafe project)



Copyright © European Commission 2013 / euronews 2013

The excellent EC Research Executive Agency’s evaluation of  Vittamed’s EC FP7 project Brainsafe. March 27, 2012

Vittamed’s project Brainsafe was favorably evaluated by European commission’s Research Executive Agency (REA). According to REA the project has been expertly run with great achievement of objectives. The quality of the science and engineering is excellent and the developed technology certainly raises the state-of-the art in this area and has potential for major impact in the intensive care as well as a number of related neurological fields. The Brainsafe non-invasive absolute intracranial pressure measurement device based on two-depth Doppler ultrasound technology has a potential to be a break through technology and is expected to be widely used in the field. 

More info at: Brainsafe description